Skip to main content

Aralast Side Effects

Generic name: alpha 1-proteinase inhibitor

Medically reviewed by Last updated on Mar 12, 2024.

Note: This document contains side effect information about alpha 1-proteinase inhibitor. Some dosage forms listed on this page may not apply to the brand name Aralast.

Applies to alpha 1-proteinase inhibitor: intravenous powder for solution, intravenous solution.

Serious side effects of Aralast

Along with its needed effects, alpha 1-proteinase inhibitor (the active ingredient contained in Aralast) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking alpha 1-proteinase inhibitor:

More common


Incidence not known

Other side effects of Aralast

Some side effects of alpha 1-proteinase inhibitor may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common


For Healthcare Professionals

Applies to alpha 1-proteinase inhibitor: intravenous powder for injection, intravenous solution.


Common (1% to 10%): Cough, dyspnea, rhinorrhea, pharyngitis

Uncommon (0.1% to 1%): Cough increased

Frequency not reported: COPD exacerbations[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness[Ref]


Common (1% to 10%): Fatigue, peripheral edema, pyrexia, chest pain, chest discomfort, lethargy

Frequency not reported: Abdominal and extremity rash

Postmarketing reports: Malaise, influenza-like illness, pain, asthenia, feeling abnormal[Ref]


Common (1% to 10%): Hot flush

Postmarketing reports: Increased blood pressure, flushing[Ref]


Common (1% to 10%): Pruritus, urticaria[Ref]


Very common (10% or more): Nausea (10.5%)

Common (1% to 10%): Diarrhea

Postmarketing reports: Vomiting[Ref]


Postmarketing reports: Hypersensitivity including anaphylactoid/anaphylactic reactions[Ref]


Common (1% to 10%): Hepatic enzyme increased[Ref]


Very common (10% or more): Musculoskeletal discomfort (16%)

Common (1% to 10%): Back pain, chills

Postmarketing reports: Arthralgia, myalgia[Ref]


Common (1% to 10%): Vessel puncture site bruise

Postmarketing reports: Injection site reaction[Ref]


Very common (10% or more): Urinary tract infection (13.2%)[Ref]


Very common (10% or more): Upper respiratory tract infection (12.5%)

Common (1% to 10%): Oral candidiasis, sinusitis

Frequency not reported: Anti-alpha 1-proteinase inhibitor (the active ingredient contained in Aralast) antibodies[Ref]


1. (2018) "Product Information. Aralast NP (alpha 1-proteinase inhibitor)." Baxter I.V. Systems Division

2. (2018) "Product Information. Glassia (alpha 1-proteinase inhibitor)." Baxter Healthcare Corporation

3. (2018) "Product Information. Prolastin-C (alpha 1-proteinase inhibitor)." Grifols USA LLC

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.